Prophylactic Effectiveness of Intravesical Mitomycin C Instillation to Prevent Recurrence of Superficial Bladder Carcinoma after Transurethral Resection.
- Author:
Dong Sun KIM
1
;
Duck Ki YOON
Author Information
1. Department of Urology, College of Medicine, Korea University, Seoul, Korea.
- Publication Type:Original Article
- Keywords:
recurrence;
superficial bladder carcinoma;
prophylacsis;
intravesical chemotherapy;
mitomycin c
- MeSH:
Drug Therapy;
Follow-Up Studies;
Humans;
Mitomycin*;
Recurrence*;
Urinary Bladder Neoplasms;
Urinary Bladder*
- From:Korean Journal of Urology
1987;28(3):351-355
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
Transurethral resection is the mainstay of curative treatment for superficial bladder cancer. Unfortunately, tumors recur in 40~70% of patients. Recently, we tried intravesical Mitomycin C chemotherapy after TUR to eliminate or decrease the frequency of recrrence. In this study, 22 patients with superficial bladder carcinoma received Mitomycin C intravesically at weekly intervals for eight weeks in dose of 40mg/40ml, starting about 48 hours after TUR. The results were compared to a group consists of 39 patients with superficial bladder cancer who received no further therapy after TUR. In the follow-up of 6 and 12 months, tumor recurrence was l3.6(3pts) and 18.2(4pts) percent respectively, in the Mitomycin C group, and 38.5(15pts, and 43.6(17 pts) per cent, respectively, in the control group. The frequency of recurrence in the Mitomycin C group was significantly less than that in the control group in the follow-up of both 6(P< 0.05) and 12 months(P< 0.05). Side effects of intravesical Mitomycin C therapy were negligibly minimal. Therefore, Mitomycin C intravesical chemotherapy after TUR is effective prophylactic treatment in reducing bladder tumor recurrence.
